Starpharma Holdings Ltd has released a press release.
DEP irinotecan phase 2 commences after positive phase 1
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- SPL7013 shows significant activity against coronavirus
- Quarterly Cashflow and Activity Report
- Okamoto licenses VivaGel antiviral condom in Asian countries
- VivaGel BV launched in Asia
- Starpharma receives US$3M milestone from AstraZeneca
Later from Starpharma
- VivaGel BV launched in central and eastern Europe
- DEP lutetium effective in human prostate cancer model
- DEP products showcased at AACR 2020
- DEP irinotecan boosts immuno-oncology in colon cancer models
- Starpharma signs new DEP partnership with Chase Sun
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma